secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001104659-25-105199
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liquidia Q3 2025: first YUTREPIA sales of $51.7M, achieves profitability, net loss narrows to $3.5M
--------------------------------------------------------------------------------

- Net product sales of YUTREPIA $51.7M in first full quarter post-launch; operating income of $1.7M, positive adjusted EBITDA $10.1M.
- Net loss narrowed to $3.5M ($0.04 loss per share) from $31.0M ($0.40 loss per share) in Q3 2024.
- More than 2,000 unique patient prescriptions and 1,500 patient starts to date, supported by 600+ prescribers.
- Cash and equivalents $157.5M at Sept 30, 2025; R&D down 21% to $9.3M; SG&A up 98% to $40.1M reflecting commercialization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465925105199/0001104659-25-105199-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465925105199/tm2530004d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-105199

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer